Skip to main content

Table 2 Demographic and clinical characteristics of the cohort of patients (full dataset)

From: Radiomics based analysis to predict local control and survival in hepatocellular carcinoma patients treated with volumetric modulated arc therapy

Sex

Female: 26 (18.4%)

Male: 112 (79.4%)

Age [years]

Mean: 64

Median: 66

St.dev: 11

Range: 30–87

Portal Vein Thrombosis

No: 64 (46.4%)

Yes: 74 (53.6%)

Tumour location

Right lobe: 57 (41.3%)

Left lobe: 10 (7.2%)

Bilateral: 71 (51.4%)

Stage T

T1: 8 (5.8%)

T2: 10 (7.2%)

T3: 120 (86.9%)

Stage N

N0: 114 (82.6%)

N1: 24 (17.4%)

Stage M

M0: 116 (84.1%)

M1: 22 (15.9%)

AJCC Stage

I: 7 (5.1%)

II: 9 (6.5%)

III: 83 (60.1%)

IV: 39 (28.3%)

Okuda Stage

I: 31 (22.4%)

II: 109 (77.6%)

BCLC Stage

A: 9 (6.5%)

B: 29 (21.0%)

C: 100 (72.5%)

Child-Pugh Stage

A: 96 (69.6%)

B: 42 (30.4%)

Hepatitis (B/C)

No: 19 (13.8%)

Yes: 119 (86.2%)

Initial Alpha-feto protein (ng/mL)

Mean: 11481

Range: 2.4, >58300

Dose prescription

54Gy: 16 (11.6%)

60Gy: 114 (82.6%)

66Gy: 8 (5.8%)

  1. Values refer to number of patients, % are relative to the total number of 138 patients